论文部分内容阅读
目的:探讨SOCS-3在非酒精性脂肪肝病(NAFLD)发病中的作用以及吡格列酮的干预作用。方法:29只雄性SD大鼠随机分为正常对照组(8只),高脂饮食组(21只)。饲养8周后,从高质饮食组随机抽取5只大鼠证实造模成功后,将该组余下的16只大鼠继续以高脂饲料喂养,并随机分为NAFLD对照组(8只);吡格列酮干预组(8只),予以吡格列酮3mg·kg-·1d-1灌胃。16周末,处死所有大鼠,检测血糖、血胰岛素、血脂、肝脏SOCS-3 mRNA和SREBP-1c mRNA表达及肝脏病理学。结果:与正常对照组相比,NAFLD组血糖、血胰岛素、血脂、肝脏脂肪变水平及肝组织SOCS-3 mRNA、SREBP1c mRNA表达显著上调。吡格列酮干预组SOCS-3 mRNA、SREBP-1c mRNA表达较NAFLD组下调,且血糖、血胰岛素、血脂、肝脏脂肪变水平下降。SOCS-3 mRNA表达水平与胰岛素抵抗指数、SREBP-1c mRNA表达水平、肝脂肪变成显著正相关。结论:SOCS-3可能通过胰岛素抵抗及上调肝组织SREBP-1c mRNA表达参与NAFLD发病,吡格列酮能抑制肝脏SOCS-3的表达,对NAFLD有一定治疗作用。
Objective: To investigate the role of SOCS-3 in the pathogenesis of non-alcoholic fatty liver disease (NAFLD) and the effect of pioglitazone. Methods: Thirty-nine male SD rats were randomly divided into normal control group (n = 8) and high fat diet group (n = 21). After feeding for 8 weeks, 5 rats were randomly selected from the high-quality diet group to confirm the success of modeling. The remaining 16 rats in the group were fed with high-fat diet and were randomly divided into NAFLD control group (n = 8); Pioglitazone intervention group (8), to pioglitazone 3mg · kg- · 1d-1 intragastric administration. At the end of 16th week, all the rats were sacrificed and blood glucose, insulin, lipids, liver SOCS-3 mRNA and SREBP-1c mRNA expression and liver pathology were detected. Results: Compared with the normal control group, the levels of blood glucose, blood insulin, lipids, hepatic steatosis and the expression of SOCS-3 mRNA and SREBP1c mRNA in NAFLD group were significantly increased. Compared with NAFLD group, the expression of SOCS-3 mRNA and SREBP-1c mRNA decreased in pioglitazone-treated group, and the levels of blood glucose, insulin, lipids and hepatic steatosis decreased. SOCS-3 mRNA expression level was positively correlated with insulin resistance index, SREBP-1c mRNA expression and hepatic steatosis. CONCLUSIONS: SOCS-3 may be involved in the pathogenesis of NAFLD through insulin resistance and upregulation of SREBP-1c mRNA in the liver. Pioglitazone may inhibit the expression of SOCS-3 in the liver and may have a therapeutic effect on NAFLD.